JPRN-jRCT2080223391已完成1 期
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Must have histologic documentation of advanced solid tumors
- •- Must have received and have progressed, are refractory or, intolerant to standard therapy and must not have a curative therapy option
排除标准
- •- Concurrent enrollment in another clinical study
- •- Prior participation in clinical studies that include durvalumab alone or in combination
- •- Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
研究者
相似试验
进行中（未招募）
不适用
A study to evaluate the safety of panitumumab and children with solid tumoursEUCTR2014-005190-36-Outside-EU/EEAAmgen Inc36
已完成
不适用
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects with Glioblastoma MultiformeGrade 4 Brain tumor10029211GlioblastomaNL-OMON41552AbbVie B.V.10
尚未招募
1 期
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000808549Bluejay Therapeutics, Inc40
尚未招募
1 期
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000809538Bluejay Therapeutics, Inc80
未知
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients with Advanced or Refractory Solid Tumors or LymphomaJPRN-jRCT2080223021Janssen Pharmaceutical K.K.33